Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
NEWARK, Calif., Feb. 16, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2015 financial results after the close of market, Monday, February 22, 2016. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
